# Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

> **NCT07685704** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhifeng Zhao, PhD** · enrollment: 46 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- HER2-positive Gastric Cancer

## Interventions

- **DRUG:** Zanidatamab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** S-1
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07685704
- **Lead sponsor:** Zhifeng Zhao, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685704, "Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07685704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*